OptiNose — Q2 2024 Earnings Presentation
16 slides from OptiNose's earnings presentation, Aug 8, 2024
Slide 1: Building a Leading ENT / Allergy Specialty Company
Building a Leading ENT / Allergy Specialty Company Corporate Presentation August 8, 2024
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this
Slide 3: Today's Agenda
3 Today’s Agenda Introduction and Key Takeaways Ramy Mahmoud, MD, MPH CS Launch Update Paul Spence Q2 2024 Performance and FY 2024 Financial Guidance Jonathan Neely Closing Remarks Ramy Mahmoud, MD, MPH
Slide 4: Key Takeaways
4 Key Takeaways • New indication creates a significant near- term growth opportunity with up to a 10x multiple on the TAM based on patients who are currently treated by a physician • Current sales footprint of 75 territories and phased modest incremental commercial investment, expected to be suffici
Slide 5: CS Launch Updates
epee CS Launch Updates
Slide 6: Commercial Update
6 Commercial Update • Core tactics: Sales Force, Non-Personal Promotion, Congresses, Peer-to-peer education • Delivered ~35,000 Calls in Q2; 60% of calls to XHANCE-naïve and low-frequency prescribers • Early indications that efficacy-focused discussions, at sufficient frequency, can lead to product
Slide 7: Addition of XHANCE to National Commercial Formularies
7 Addition of XHANCE to National Commercial Formularies As announced at the end of June, XHANCE was added to Express Scripts’ national formularies including the National Preferred, Flex, and Basic formularies These formularies are among the largest commercial formularies in the U.S. with more than 2
Slide 8: Q2 2024 Performance
epee Q2 2024 Performance
Slide 9: Financial Review – Second Quarter 2024
9 Financial Review – Second Quarter 2024 Average net revenue per prescription increased 44% YoY in context of our focus on growing profitable prescriptions XHANCE Net Revenues of $20.5 million increased 5% compared to Q2 2023 As expected, Operating Expenses increased ~$4M $21.1 $25.1 Q2 '23 Q2 '24 (
Slide 10: Financial Review – YTD June 2024
10 Financial Review – YTD June 2024 Average net revenue per prescription increased 51% YoY in context of our focus on growing profitable prescriptions XHANCE Net Revenues of $35.4 million increased 13% compared to YTD June 2023 As expected, Operating Expenses increased ~$1M $45.6 $46.8 YTD June '23
Slide 11: 2024 Outlook
epee 2024 Outlook
Slide 12: Full Year 2024 Financial Guidance
12 Full Year 2024 Financial Guidance GAAP Operating Expenses (SG&A and R&D Expenses) Expected to be between $95 to $101 million; approximately $6 million of which represents stock-based compensation XHANCE Net Revenue FY 2024 expected to be between $85 to $90 million, an increase of 20% to 27% compa
Slide 13: Closing Remarks
Closing Remarks
Slide 14: Key Takeaways
14 Key Takeaways • New indication creates a significant near- term growth opportunity with up to a 10x multiple on the TAM based on patients who are currently treated by a physician • Current sales footprint of 75 territories and phased modest incremental commercial investment, expected to be suffic
Slide 15: Investor Relations – Optinose
15 Investor Relations – NASDAQ: OPTN Optinose Investor ContactAnalyst Coverage 1 Jefferies: Glen Santangelo Lake Street: Thomas Flaten Piper Sandler: David Amsellem H. C. Wainwright: Matthew Caufield 1 - Optinose is followed by the analysts listed above. Please note that any opinions, estimates or f
Slide 16: Building a Leading ENT / Allergy Specialty Company
Building a Leading ENT / Allergy Specialty Company Corporate Presentation August 8, 2024